Amphera’s MesoPher cell therapy demonstrates favourable safety and promising survival in a phase II clinical trial in resected pancreatic cancer

04 May 2022

Positive results from first cohort of 10 patients from REACtiVe study published in European Journal of Cancer

`s-Hertogenbosch, The Netherlands; May 4, 2022. Amphera B.V. announces positive REACtiVe Phase 2 study safety and efficacy data from the first cohort of 10 patients receiving Amphera’s MesoPher dendritic cell therapy. Patients, with resected pancreatic cancer who had completed standard-of-care chemotherapy, received 3 bi-weekly injections of MesoPher and booster injections at 4 and 7 months. The results from this first cohort have been published in the European Journal of Cancer1.

The latest REACtiVe data showed an average Overall Survival after surgery of approximately 36 months,

Read more »